The global Postpartum Depression Drugs Market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.
According
to the Indian Association of Preventive & Social Medicine, every year,
around 30 million women experience pregnancy, and 27 million women have live
childbirths. In July 2022, the Government of India launched several
schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and
Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government
offers free of cost treatment related to pregnancy, such as diagnostics,
medicines, and other consumables. Thus, initiatives like JSSK and JSY support
women in completing treatment such as postpartum depression, simultaneously
driving market growth during the forecast period.
Another
significant factor driving the adoption of postpartum depression drugs is
rising healthcare expenditures, which help to improve infrastructure and
improve patient access to healthcare facilities. According to
the PETERSON-KFF Health System Tracker report, women spend around USD
18,865 annually on pregnancy, childbirth, and postpartum treatment. There is
significant variation. around this, spending and costs vary significantly by
region worldwide. The increasing access of women to PPD drug treatment is
anticipated to drive market growth in the coming years.
Request a free sample copy or view report
summary: Postpartum Depression Drugs Market Report
Postpartum
Depression Drugs Market Report Highlights
- The
postpartum anxiety segment held the largest share of the market in 2023.
This can be attributed to the disease's high treatment rate and growing
prevalence in developed and developing countries.
- Based on the
treatment type, the hormonal therapy segment is expected to grow at the
fastest CAGR during the forecast period.This can be attributed to the
development and commercialization of new hormonal drugs and increased
adoption by smaller hospitals and facilities for the treatment of PDD.
- In 2023, the
oral segment held the largest share of the market based on the route of
administration. This dominance can be attributed to the increase in the
prevalence and incidence of disease worldwide, the large availability of
products, and the rising demand for new generic oral drugs for treatment.
- The hospital
pharmacy segment held the largest share of the market based on
distribution channels in 2023. Hospital treatment rates, patient
preference for hospitals over other healthcare settings for PDD treatment,
and the increasing number of patients visiting hospitals.
- North America
dominated the market owing to factors such as advanced healthcare
infrastructure, rising disease prevalence, and favorable regulatory
environment.
Postpartum
Depression Drugs Market Segmentation
Grand
View Research has segmented the postpartum depression drugs market based on
type, treatment, route of administration, distribution channel, and region:
Postpartum
Depression Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)
- Postpartum
Blues
- Postpartum
Anxiety
- Postpartum
Obsessive-Compulsive Disorder (OCD)
- Postpartum
Post-Traumatic Stress Disorder (PTSD)
- Postpartum
Panic Disorder
- Postpartum
Psychosis
Postpartum
Depression Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)
- Pharmacotherapy
- Hormonal
Therapy
- Others
Route
of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Parenteral
- Oral
- Others
Postpartum
Depression Drugs Distribution Channel Outlook (Revenue, USD Million, 2018
- 2030)
- Hospital
Pharmacy
- Retail
Pharmacy
- Others
(online pharmacy)
Postpartum
Depression Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East
and Africa (MEA)
- South Africa
- Saudi Arabia
- Kuwait
- UAE
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com